Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
151 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015', provides an overview of the Streptococcus Pneumoniae Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Streptococcus Pneumoniae Infection Overview 9 Therapeutics Development 10 Pipeline Products for Streptococcus Pneumoniae Infection - Overview 10 Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis 11 Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies 12 Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes 16 Streptococcus Pneumoniae Infection - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Streptococcus Pneumoniae Infection - Products under Development by Companies 20 Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes 23 Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development 24 Abera Bioscience AB 24 Allergan Plc 25 Alvogen Korea 26 Arsanis Biosciences GmbH 27 AstraZeneca Plc 28 Beijing Minhai Biotechnology Co., Ltd 29 ContraFect Corporation 30 Daiichi Sankyo Company, Limited 31 Eurocine Vaccines AB 32 FluGen, Inc. 33 GlaxoSmithKline Plc 34 ImmunoBiology Limited 35 Lascco SA 36 Liquidia Technologies, Inc. 37 Melinta Therapeutics, Inc 38 Merck & Co., Inc. 39 Mucosis B.V. 40 Panacea Biotec Limited 41 Prometheon Pharma, LLC 42 Sanofi Pasteur SA 43 Serum Institute of India Limited 44 Sinovac Biotech Ltd. 45 SK Chemicals Co., Ltd. 46 Sumitomo Dainippon Pharma Co., Ltd. 47 Valneva SE 48 Vaxxilon AG 49 Virometix AG 50 Walvax Biotechnology Co., Ltd. 51 Wellstat Vaccines, LLC 52 Wockhardt Limited 53 Streptococcus Pneumoniae Infection - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Combination Products 55 Assessment by Target 56 Assessment by Mechanism of Action 58 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 Ab-01 - Drug Profile 64 acorafloxacin hydrochloride - Drug Profile 65 Antibodies for Pneumococcus Infections - Drug Profile 68 ASN-400 - Drug Profile 69 AZ-6142 - Drug Profile 70 CAL-02 - Drug Profile 71 CF-303 - Drug Profile 72 CF-309 - Drug Profile 73 DEF-201 - Drug Profile 74 GSK-2189242A - Drug Profile 76 GSK-2830929A - Drug Profile 77 GSK-2830930A - Drug Profile 78 LCB-010371 - Drug Profile 79 Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile 81 Monoclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders - Drug Profile 82 NBP-606 - Drug Profile 83 Nucovac - Drug Profile 84 pneumococcal (13-valent) vaccine - Drug Profile 85 pneumococcal (13-valent) vaccine - Drug Profile 86 pneumococcal (23-valent) vaccine - Drug Profile 87 pneumococcal (monovalent) vaccine - Drug Profile 88 pneumococcal (trivalent) vaccine - Drug Profile 89 pneumococcal [serotype 4 and 6A] vaccine - Drug Profile 90 pneumococcal [TIGR4] vaccine - Drug Profile 91 pneumococcal polysaccharide (13-valent) vaccine - Drug Profile 92 pneumococcal polysaccharide (23-valent) vaccine - Drug Profile 93 pneumococcal vaccine - Drug Profile 94 pneumococcal vaccine - Drug Profile 95 pneumococcal vaccine - Drug Profile 96 pneumococcal vaccine - Drug Profile 97 pneumococcal vaccine - Drug Profile 98 pneumococcal vaccine - Drug Profile 99 pneumococcal vaccine - Drug Profile 100 pneumococcal vaccine - Drug Profile 101 pneumococcal vaccine - Drug Profile 102 pneumococcal vaccine - Drug Profile 103 pneumococcus vaccine - Drug Profile 104 PneumoMab - Drug Profile 105 PnuBioVax - Drug Profile 106 PPV-23 - Drug Profile 107 RXP-873 - Drug Profile 108 SIILPCV-10 - Drug Profile 109 SM-295291 - Drug Profile 110 SM-369926 - Drug Profile 111 Small Molecule for Respiratory Tract Infections - Drug Profile 112 Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile 113 Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia - Drug Profile 114 Small Molecules for Streptococcus Pneumoniae Infections - Drug Profile 115 Small Molecules to Inhibit CBPs for Pneumococcus Infections - Drug Profile 116 Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 117 streptococcal pneumoniae vaccine - Drug Profile 118 streptococci pneumoniae vaccine - Drug Profile 119 streptococcus pneumonia vaccine - Drug Profile 120 streptococcus pneumoniae vaccine - Drug Profile 121 streptococcus pneumoniae vaccine (whole-cell) - Drug Profile 122 Synthetic Peptides for Bacterial Infections - Drug Profile 124 typhoid + pneumococcal vaccine - Drug Profile 125 V-114 - Drug Profile 126 VMT-1 - Drug Profile 127 WCK-4873 - Drug Profile 128 Streptococcus Pneumoniae Infection - Recent Pipeline Updates 129 Streptococcus Pneumoniae Infection - Dormant Projects 135 Streptococcus Pneumoniae Infection - Discontinued Products 138 Streptococcus Pneumoniae Infection - Product Development Milestones 139 Featured News & Press Releases 139 Appendix 146 Methodology 146 Coverage 146 Secondary Research 146 Primary Research 146 Expert Panel Validation 146 Contact Us 146 Disclaimer 147
List of Tables
Number of Products under Development for Streptococcus Pneumoniae Infection, H2 2015 14 Number of Products under Development for Streptococcus Pneumoniae Infection - Comparative Analysis, H2 2015 15 Number of Products under Development by Companies, H2 2015 17 Number of Products under Development by Companies, H2 2015 (Contd..1) 18 Number of Products under Development by Companies, H2 2015 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2015 20 Comparative Analysis by Late Stage Development, H2 2015 21 Comparative Analysis by Clinical Stage Development, H2 2015 22 Comparative Analysis by Early Stage Development, H2 2015 23 Products under Development by Companies, H2 2015 24 Products under Development by Companies, H2 2015 (Contd..1) 25 Products under Development by Companies, H2 2015 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2015 27 Streptococcus Pneumoniae Infection - Pipeline by Abera Bioscience AB, H2 2015 28 Streptococcus Pneumoniae Infection - Pipeline by Allergan Plc, H2 2015 29 Streptococcus Pneumoniae Infection - Pipeline by Alvogen Korea, H2 2015 30 Streptococcus Pneumoniae Infection - Pipeline by Arsanis Biosciences GmbH, H2 2015 31 Streptococcus Pneumoniae Infection - Pipeline by AstraZeneca Plc, H2 2015 32 Streptococcus Pneumoniae Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 33 Streptococcus Pneumoniae Infection - Pipeline by ContraFect Corporation, H2 2015 34 Streptococcus Pneumoniae Infection - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 35 Streptococcus Pneumoniae Infection - Pipeline by Eurocine Vaccines AB, H2 2015 36 Streptococcus Pneumoniae Infection - Pipeline by FluGen, Inc., H2 2015 37 Streptococcus Pneumoniae Infection - Pipeline by GlaxoSmithKline Plc, H2 2015 38 Streptococcus Pneumoniae Infection - Pipeline by ImmunoBiology Limited, H2 2015 39 Streptococcus Pneumoniae Infection - Pipeline by Lascco SA, H2 2015 40 Streptococcus Pneumoniae Infection - Pipeline by Liquidia Technologies, Inc., H2 2015 41 Streptococcus Pneumoniae Infection - Pipeline by Melinta Therapeutics, Inc, H2 2015 42 Streptococcus Pneumoniae Infection - Pipeline by Merck & Co., Inc., H2 2015 43 Streptococcus Pneumoniae Infection - Pipeline by Mucosis B.V., H2 2015 44 Streptococcus Pneumoniae Infection - Pipeline by Panacea Biotec Limited, H2 2015 45 Streptococcus Pneumoniae Infection - Pipeline by Prometheon Pharma, LLC, H2 2015 46 Streptococcus Pneumoniae Infection - Pipeline by Sanofi Pasteur SA, H2 2015 47 Streptococcus Pneumoniae Infection - Pipeline by Serum Institute of India Limited, H2 2015 48 Streptococcus Pneumoniae Infection - Pipeline by Sinovac Biotech Ltd., H2 2015 49 Streptococcus Pneumoniae Infection - Pipeline by SK Chemicals Co., Ltd., H2 2015 50 Streptococcus Pneumoniae Infection - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 51 Streptococcus Pneumoniae Infection - Pipeline by Valneva SE, H2 2015 52 Streptococcus Pneumoniae Infection - Pipeline by Vaxxilon AG, H2 2015 53 Streptococcus Pneumoniae Infection - Pipeline by Virometix AG, H2 2015 54 Streptococcus Pneumoniae Infection - Pipeline by Walvax Biotechnology Co., Ltd., H2 2015 55 Streptococcus Pneumoniae Infection - Pipeline by Wellstat Vaccines, LLC, H2 2015 56 Streptococcus Pneumoniae Infection - Pipeline by Wockhardt Limited, H2 2015 57 Assessment by Monotherapy Products, H2 2015 58 Assessment by Combination Products, H2 2015 59 Number of Products by Stage and Target, H2 2015 61 Number of Products by Stage and Mechanism of Action, H2 2015 63 Number of Products by Stage and Route of Administration, H2 2015 65 Number of Products by Stage and Molecule Type, H2 2015 67 Streptococcus Pneumoniae Infection Therapeutics - Recent Pipeline Updates, H2 2015 133 Streptococcus Pneumoniae Infection - Dormant Projects, H2 2015 139 Streptococcus Pneumoniae Infection - Dormant Projects (Contd..1), H2 2015 140 Streptococcus Pneumoniae Infection - Dormant Projects (Contd..2), H2 2015 141 Streptococcus Pneumoniae Infection - Discontinued Products, H2 2015 142
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
